SNGX - Soligenix, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.0400
-0.1200 (-3.80%)
As of 10:42AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.1600
Open3.1400
Bid3.0400 x 3200
Ask3.0500 x 900
Day's Range2.8000 - 3.1400
52 Week Range0.6500 - 3.5400
Volume180,641
Avg. Volume385,620
Market Cap62.785M
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks Small Cap Research

    SNGX: KOL Interview with Dr. Brian Poligone, an Investigator in P3 FLASH Study in CTCL…

    By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Soligenix, Inc. (NASDAQ:SNGX) is currently conducting a Phase 3 clinical trial of SGX301 in patients with cutaneous T cell lymphoma (CTCL). The FLASH (Fluorescent Light Activated Synthetic Hypericin) trial is a randomized, double blind, placebo controlled study that was originally expected to enroll approximately 120 subjects with

  • Benzinga

    The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: ...

  • Is Soligenix (NASDAQ:SNGX) In A Good Position To Deliver On Growth Plans?
    Simply Wall St.

    Is Soligenix (NASDAQ:SNGX) In A Good Position To Deliver On Growth Plans?

    Just because a business does not make any money, does not mean that the stock will go down. For example, Soligenix...

  • Zacks Small Cap Research

    SNGX: Interview with Dr. Straube Regarding the Upcoming Phase 3 CTCL Data Readout…

    By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Interview with Dr. Richard Straube Regarding Upcoming Phase 3 Data for SGX301 in CTCL Soligenix, Inc. (NASDAQ:SNGX) recently announced the completion of enrollment in the Phase 3 clinical trial of SGX301 in patients with cutaneous T cell lymphoma (CTCL). The FLASH (Fluorescent Light Activated Synthetic Hypericin)

  • How Much is Soligenix, Inc.'s (NASDAQ:SNGX) CEO Getting Paid?
    Simply Wall St.

    How Much is Soligenix, Inc.'s (NASDAQ:SNGX) CEO Getting Paid?

    Christopher Schaber became the CEO of Soligenix, Inc. (NASDAQ:SNGX) in 2006. First, this article will compare CEO...

  • SNGX: CTCL Phase 3 Trial Fully Enrolled; Data in 1Q20…
    Zacks Small Cap Research

    SNGX: CTCL Phase 3 Trial Fully Enrolled; Data in 1Q20…

    By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 Trial of SGX301 in CTCL Fully Enrolled; Data in 1Q20 On December 3, 2019, Soligenix, Inc. (NASDAQ:SNGX) announced that enrollment has completed in the Phase 3 clinical trial of SGX301 in patients with cutaneous T cell lymphoma (CTCL). The FLASH (Fluorescent Light Activated Synthetic Hypericin) trial is a

  • PR Newswire

    Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX301 in the Treatment of Cutaneous T-cell Lymphoma

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has completed patient enrollment in its Phase 3 "Fluorescent Light Activated Synthetic Hypericin" (FLASH) study for SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). The study successfully enrolled 169 subjects, following positive interim analysis, which included a prospectively defined, unblinded assessment of the study's primary efficacy endpoint by an independent Data Monitoring Committee (DMC). With enrollment completed, top-line results are expected in the first quarter of 2020.

  • If You Had Bought Soligenix (NASDAQ:SNGX) Stock Five Years Ago, You'd Be Sitting On A 94% Loss, Today
    Simply Wall St.

    If You Had Bought Soligenix (NASDAQ:SNGX) Stock Five Years Ago, You'd Be Sitting On A 94% Loss, Today

    Soligenix, Inc. (NASDAQ:SNGX) shareholders should be happy to see the share price up 12% in the last month. But will...

  • SNGX: Two Phase 3 Data Readouts Over the Next Two Quarters…
    Zacks Small Cap Research

    SNGX: Two Phase 3 Data Readouts Over the Next Two Quarters…

    By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Two Phase 3 Data Readouts in 2020 Soligenix, Inc. (NASDAQ:SNGX) is a late-stage clinical biopharmaceutical company developing treatments in oncology, GI disorders, and biodefense. The company has a number of important near-term catalysts that we believe should be on investor’s radars, including: • 1Q2020 – topline

  • Zacks Small Cap Research

    SNGX: Q&A on SGX942 Phase 3 Trial Interim Analysis…

    On August 28, 2019, Soligenix, Inc. (SNGX) announced a positive recommendation from the independent Data Monitoring Committee (DMC) to continue enrollment in the ongoing Phase 3 clinical trial of SGX942 in the treatment of oral mucositis in patients with head and neck cancer. The DMC recommended that approximately 70 additional subjects be randomized into the trial to maintain the 90% statistical power for the primary outcome, which will increase the study sample size from 190 to 260 subjects. The increase in study sample size was required to account for any potential variability observed in the Phase 3 trial that differs from the trials original design assumptions.

  • Benzinga

    The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines ...

  • Zacks Small Cap Research

    SNGX: Interim Analysis for Phase 3 Oral Mucositis Trial Imminent

    Soligenix, Inc. (SNGX) is a late-stage clinical biopharmaceutical company developing treatments in oncology, GI disorders, and biodefense. In April 2019, Soligenix announced that the Phase 3 trial of SGX942 had reached the enrollment target to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC).

  • Moleculin Completes Enrollment in Early-Stage Cancer Study
    Zacks

    Moleculin Completes Enrollment in Early-Stage Cancer Study

    Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.

  • Zacks Small Cap Research

    SNGX: What to Expect from the Upcoming Interim Analysis of SGX942

    Soligenix, Inc. (SNGX) is a biopharmaceutical company currently conducting two pivotal Phase 3 clinical trials with its lead development compounds. • SGX301 is in a Phase 3 trial for the treatment of cutaneous T cell lymphoma (CTCL). • SGX942 is in a Phase 3 clinical trial for the treatment of oral mucositis in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy.

  • Zacks Small Cap Research

    SNGX: Multiple Important Catalysts on the Horizon…

    Soligenix, Inc. (SNGX) is a late-stage clinical biopharmaceutical company developing treatments in oncology, GI disorders, and biodefense. In April 2019, Soligenix announced that the Phase 3 trial of SGX942 had reached the enrollment target to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC).

  • Zacks Small Cap Research

    SNGX: Interim Analysis for SGX942 Phase 3 Trial Expected in Sep. 2019…

    On April 18, 2019, Soligenix, Inc. (SNGX) announced that it has reached the enrollment target for the Phase 3 clinical trial of SGX942 (dusquetide) to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC). The Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) clinical trial is evaluating SGX942 for the treatment of sever oral mucositis (OM) in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy.

  • Zacks Small Cap Research

    SNGX: Enrollment Target Reached for Interim Analysis of SGX942 Phase 3 Trial…

    On April 18, 2019, Soligenix, Inc. (SNGX) announced that it has reached the enrollment target for the Phase 3 clinical trial of SGX942 (dusquetide) to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC). The Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) clinical trial is evaluating SGX942 for the treatment of sever oral mucositis (OM) in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy.

  • Zacks Small Cap Research

    SNGX: Interim Analysis of SGX942 in Oral Mucositis in Third Quarter of 2019…

    Soligenix, Inc. (SNGX) is currently conducting the randomized, multinational, double blind, placebo controlled Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) clinical trial, which is evaluating SGX942 (dusquetide) for the treatment of severe oral mucositis (OM) in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy. Important secondary endpoints that are being evaluated include tumor progression and overall survival at 12 months.